Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 19.


Lefebvre, Carol, Glanville, Julie ORCID: 0000-0002-1253-8524, Beale, Sophie ORCID: 0000-0003-0164-103X, Boachie, Charles, Duffy, Steven ORCID: 0000-0001-7335-8167, Fraser, Cynthia, Harbour, Jenny, McCool, Rachael and Smith, Lynne
(2017) Assessing the performance of methodological search filters to improve the efficiency of evidence information retrieval: five literature reviews and a qualitative study. Health technology assessment (Winchester, England), 21 (69). 1 - 148.


Stainthorpe, Angela, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Dundar, Yenal ORCID: 0000-0002-9847-1622, McEntee, Joanne and Syndikus, Isabel
(2020) Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open, 4 (4). 563 - 574.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Stainthorpe, Angela, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty ORCID: 0000-0002-7097-8704, Boland, Angela, Beale, Sophie, Dundar, Yenal, Kotas, Eleanor, McEntee, Joanne and Isabel, Syndikus
(2018) Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12). [Report]


Lambe, Tosin ORCID: 0000-0002-6229-2454, Duarte, Rui, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Kotas, Eleanor, McEntee, Joanne and Pomeroy, Ian
(2019) Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 37 (3). 345 - 357.


Duarte, Rui, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Boland, Angela, Beale, Sophie, Kotas, Eleanor and Mcentee, Joanne
(2017) Cladribine for the treatment of relapsing-remitting multiple sclerosis. [Report]


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela, Dickson, Rumona ORCID: 0000-0003-1416-0913, Dwan, Kerry, Richardson, Marty, Dundar, Yenal, Davis, Helen and Banks, Lindsay
(2015) Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33 (9). 893 - 904.


Houten, Rachel ORCID: 0000-0002-4315-7732, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela, Lambe, Tosin, Dundar, Yenal ORCID: 0000-0002-9847-1622, Kotas, Eleanor and McEntee, Joanne
(2021) Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open, 5 (1). 13 - 22.


Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela, Dwan, Kerry, Beale, Sophie ORCID: 0000-0003-0164-103X, Hockenhull, Juliet, Proudlove, Christine, Dundar, Yenal, Richardson, Marty, Dickson, Rumona ORCID: 0000-0003-1416-0913
et al (show 2 more authors) (2015) Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19 (47). I - 133.


Beale, Sophie
(2021) Keeping horses barefoot: a shared accomplishment. PhD thesis, University of Liverpool.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Bagust, Adrian ORCID: 0000-0002-2142-5767, Richardson, Marty, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela, Dundar, Yenal, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Hounsome, Juliet ORCID: 0000-0002-2026-3778, Duarte, Rui
et al (show 1 more authors) (2020) Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24 (2). 1 - +.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela, Dwan, Kerry, Chaplin, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie, Kotas, Eleanor, Banks, Lindsay and Greystoke, Alastair
(2014) Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer. [Report]


Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Bagust, Adrian ORCID: 0000-0002-2142-5767, Richardson, Marty, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Duarte, Rui, Kotas, Eleanor, Banks, Lindsay and Palmer, Daniel ORCID: 0000-0002-7147-5703
(2018) Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36 (10). 1153 - 1163.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Abdulla, Ahmed, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Richardson, Marty, Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Boland, Angela, Kotas, Eleanor, McEntee, Joanne and Palmer, Daniel ORCID: 0000-0002-7147-5703
(2018) Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36 (3). 289 - 299.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Dwan, Kerry, Dickson, Rumona ORCID: 0000-0003-1416-0913, Proudlove, Chris and Dundar, Yenal
(2015) Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33 (1). 13 - 23.


Hounsome, Juliet ORCID: 0000-0002-2026-3778, Pilkington, Gerlinde ORCID: 0000-0003-0028-0746, Mahon, James, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Kotas, Eleanor, Renton, Tara and Dickson, Rumona ORCID: 0000-0003-1416-0913
(2020) Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health Technology Assessment, 24 (30).


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Richardson, Marty, Krishan, Ashma, Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Abdulla, Ahmed, Kotas, Eleanor, Banks, Lindsay
et al (show 1 more authors) (2017) Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35 (10). 1035 - 1046.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela, Beale, Sophie, Chaplin, Marty ORCID: 0000-0002-7097-8704, Krishan, Ashma, Stainthorpe, Angela, Abdulla, Ahmed, Kotas, Eleanor, Banks, Lindsay
et al (show 1 more authors) (2016) Talimogene laherparepvec for treating metastatic melanoma. [Report]


Nicholson, Amanda, Mahon, James, Boland, Angela, Beale, Sophie ORCID: 0000-0003-0164-103X, Dwan, Kerry, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Hockenhull, Juliet and Dundar, Yenal
(2015) The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19 (87). 1 - +.


Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela, Dundar, Yenal, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Duarte, Rui and Shenoy, Aditya
(2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19 (1).

This list was generated on Mon Apr 26 05:53:18 2021 BST.